Alimera Sciences, Inc. announces that it will report third quarter financial results on October 26, 2023, prior to the market open.
Conference Call to be held the same day at 9:00am Eastern Time
ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report third quarter financial results on October 26, 2023, prior to the market open.
Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10183110/fa99503540
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.
The conference call will also be available through live webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=8U00zjTj
And is also available through the company’s website.
A webcast replay of the call will be available approximately one hour after the end of the call through January 26, 2024. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code #4883233. The telephonic replay will be available until November 9, 2023.
About Alimera Sciences, Inc.
Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |